Sarcoidosis is a systemic disease of unknown aetiology that is characterized by granulomatous inflammation that can develop in almost any organ system. Musculoskeletal manifestations are seen in up to one-third of patients, ranging from arthralgia through to widespread destructive bone lesions. Inflammatory tendon lesions and periarticular swelling are more common than true joint synovitis. Despite advances in our understanding of the pathophysiology of the disease, diagnosis remains challenging. Definitive diagnosis, irrespective of organ site involvement, hinges on histological confirmation of non-caseating granuloma combined with an appropriate clinical syndrome. Musculoskeletal involvement usually develops early in the disease course. Imaging modalities, particularly fluorodeoxyglucose PET, are helpful in delineating the extent of involvement and measuring disease activity. Bone involvement may only become apparent following isotope imaging. Corticosteroids remain the cornerstone of treatment. MTX is the steroid-sparing agent of choice unless there is renal involvement. Biologic therapies are sometimes used in severe disease, although the evidence base for efficacy is inconsistent.
Introduction
The purpose of this review article is to summarize sarcoidosis in a manner relevant to rheumatologists. Sarcoidosis is systemic inflammatory disease characterised by noncaseating granulomata (Fig. 1) . The disease is known for its myriad of presentations, frequently crossing the specialist boundaries of medicine. The earliest descriptions of sarcoidosis are from Hutchinson, a 19th century London clinician whose skills were suitably diverse with practices in internal medicine, dermatology, venereal disease, ophthalmology and surgery. In 1858 Hutchinson encountered a 58-year-old coal wharf employee who presented with purple symmetrical skin plaques on his legs and hands that had developed gradually over the preceding 2 years [1] . To the best of our knowledge, this was the index case report of sarcoidosis in the medical literature.
The granuloma formation is the end of a coordinated Th1 cytokine response that induces macrophages to differentiate to epithelioid cells and fuse to form giant cells [2] . As the granuloma develops, the central areas become tightly packed with macrophages, epithelioid cells and multinucleated giant cells surrounded by a peripheral rim consisting of CD8 T cells, mast cells and fibroblasts. Most cases resolve spontaneously, but in 2025% of patients obliterative fibrosis develops [3] .
The epidemiology of the disease remains poorly defined. Cases are reported worldwide in all races and sexes, although the incidence peaks in young adults and the disease is more frequent in people of black ethnicity [4] .
Musculoskeletal manifestations are seen in one-quarter to one-third of patients, with joint, bone and muscle involvement all possible. The severity of musculoskeletal involvement is also very variable, ranging from arthralgia through to widespread destructive bone lesions.
A rheumatologist may encounter sarcoidosis in several situations: when sarcoidosis presents with primary musculoskeletal symptoms, when a patient with established sarcoidosis develops new musculoskeletal symptoms and when advice is sought on immunosuppression. This article will review the musculoskeletal manifestations of the disease and address these scenarios.
Diagnosing sarcoidosis
A diagnosis of sarcoidosis is often challenging and never absolute. In its simplest manifestation with cough, interstitial lung disease and hilar adenopathy, the diagnosis still rests upon the combination of the characteristic syndrome with histological confirmation of non-caseating granuloma. When the clinical syndrome is less clear, or when tissue is not accessible for histological analysis, the diagnosis becomes less certain. A crucial skill for any physician involved with sarcoidosis is the ability to retain an open mind.
One thing that is helpful to appreciate is the disease tends to declare itself early on. If an organ system has not been involved after 35 years of the disease, it is unusual (but not impossible) to accrue new involvement. Therefore, when a new symptom emerges in a patient who has a sarcoidosis diagnosis dating back several years, it is important to consider all possibilities.
The appearance of the granuloma in sarcoidosis is not distinguishable from those observed in other granulomatous disorders, although the presence of asteroid bodies is supportive (Fig. 1) [57] . Certain infections, including tuberculosis mycobacterium, IBD, systemic vasculitis and lymphoproliferative disorders, are established causes of granulomatous inflammation, all of which have musculoskeletal manifestations. Granulomas occurring outside of the typical syndromes associated with sarcoidosis should arouse suspicion of alternative diagnoses.
Serum angiotensin-converting enzyme (ACE) levels have been widely used as a diagnostic biomarker for sarcoidosis, but they are neither sensitive nor specific and correlate poorly with disease activity [8, 9] . In clinical practice, serum ACE is of limited value in the diagnosis of sarcoidosis, and outside of a clinical syndrome compatible with sarcoidosis, elevated serum ACE can be a distracting result.
Imaging modalities are helpful in defining the extent of organ involvement in sarcoidosis. Lesions have significantly increased uptake of fluorodeoxyglucose (FDG) and thus PET-CT has advanced the identification of these lesions. Despite this, PET-CT and other imaging modalities are non-specific in their diagnostic capabilities, unable to confirm by imaging alone the diagnosis of sarcoidosis. Their greatest value is in the ability to identify sites for potential tissue diagnosis as well as quantify disease activity. A suspected cutaneous deposit is often the easiest and most accessible way of confirming the diagnosis (Fig. 2 ).
Rheumatic manifestations of sarcoidosis
Acute arthritis (Lö fgren's syndrome)
The most frequent musculoskeletal manifestation of sarcoidosis is an acute arthritis that occurs as part of Lö fgren's syndrome: the triad of symmetric hilar adenopathy, joint pain and erythema nodosum [10] . The syndrome is seasonal, with clusters during springtime [11] . Interestingly, the condition is associated with specific genetic factors that may distinguish it from other manifestations of sarcoidosis. There is a strong association with the HLA-DRB1 alleles and HLA-DRB1*03-positive Lö fgren's patients have an excellent prognosis [12] .
The ankles are the most frequently involved joint, bilateral in the majority of patients [13] . Joint involvement can extend to other sites including the knees, wrist, elbows and MCP joints. On US imaging, joint swelling is usually attributable to periarticular soft tissue swelling and tenosynovitis. True joint synovitis or effusions are rare and, if present, are usually minor and without power Doppler activity [14] . SF analysis is not required for diagnosis but, when performed, reveals a mild inflammatory infiltrate with a predominance of mononuclear cells. Histopathological examination of synovium typically does not demonstrate a granulomatous reaction [15] .
Chest radiographs reveal bilateral hilar adenopathy in 90% of patients, which is asymptomatic [13] . Erythema nodosum is not universal, occurring in 40% of patients and reported more frequently in Caucasians and women [16] . Fever and other constitutional symptoms may be present.
The natural course of Lö fgren's syndrome is complete resolution, settling over a few months. In a minority of cases the duration until complete resolution is longer (1824 months) [16] . Only a very small proportion experience relapse of the disease after resolution. Joint destruction in Lö fgren's syndrome is extremely rare [17] .
The clinical syndrome of Lö fgren's is so characteristic that patient history, examination and chest radiograph are usually sufficient to reach a diagnosis: this is the one scenario where histological confirmation need not be sought.
When considering a diagnosis of Lö fgren's syndrome it is sensible to acknowledge other causes of erythema nodosum that occur in association with polyarthritis and hilar adenopathy, including bacterial, fungal and viral infections. Awareness that hilar adenopathy is usually asymptomatic is important, and the presence of respiratory symptoms should trigger suspicion. In high-risk patients or areas where diseases such as tuberculosis, histoplasmosis and coccidioidomycosis occur, biopsy and appropriate stains and cultures should be performed.
Chronic arthritis
Chronic sarcoidosis-related arthritis usually occurs in the context of other extrapulmonary manifestations, particularly skin involvement [1820] . The typical pattern is a symmetric, medium to large joint oligoarthritis [13, 21] . It is important to distinguish true synovitis from tenosynovitis, as the latter is more frequently observed. Symmetric inflammatory lesions of the extensor tendon compartment of the wrists should prompt suspicion of musculoskeletal sarcoidosis. Destructive arthritis is less frequently described [22] . When true synovitis in large joints is observed, further evaluation is warranted. SF analysis is not diagnostic, although it does tend to reveal a milder inflammatory infiltrate compared with other arthritides, with a predominance of lymphocytes [23] . Synovial tissue should be obtained to demonstrate granulomatous infiltrate as well as to exclude other diagnoses, such as infection (especially tuberculosis). Sarcoid monoarthritis is rare in cohort studies, although many case reports exist, perhaps suggesting a reporting bias. Exclusion of gout, calcium pyrophosphate and septic arthritis is necessary. A relationship between gout and sarcoidosis has been appreciated for decades. It is thought to be secondary to altered urate metabolism leading to hyperuricaemia [24] . The diagnosis of gouty arthritis in sarcoidosis should be confirmed by joint aspiration and documentation of the sodium monourate crystals.
Jaccoud's Jaccoud's arthropathy is characterized by a deforming but non-erosive arthritis. It is classically described in CTD, specifically SLE. Jaccoud's arthritis in sarcoidosis has been described in case reports [25] . It usually presents in the context of extensive internal organ involvement later during the disease course. Biopsy reveals fibrosis of the tendons with granulomas of epithelioid cells in the muscles and tendon sheets.
Axial disease
Spinal involvement in sarcoidosis is often asymptomatic and the true prevalence is unknown. Vertebral lesions may be the initial symptom or can be identified incidentally when patients undergo radioisotope imaging for other reasons https://academic.oup.com/rheumatology (e.g. to assess lung disease activity) [26] . Spinal lesions may appear lytic, sclerotic or both and can involve any segment of the spine [27] . Sacroiliitis in sarcoidosis is described in several case reports [28] . While the prevalence in the general population of SpA ranges from 1 to 1.9%, Erb et al. [29] reported a 6% prevalence of SpA in patients with sarcoidosis, suggesting a possible association between the two conditions. Involvement may be unilateral and biopsy will typically confirm granulomatous disease [30] .
Dactylitis
Dactylitis is one of the most familiar appearances of musculoskeletal involvement in sarcoidosis. Most clinicians are familiar with this pattern of disease, which is almost exclusively associated with chronic systemic involvement. It has been described in coexistence with lupus pernio and other forms of chronic cutaneous sarcoidosis. It typically develops in a symmetrical pattern, most often affecting the second and third phalanges, preserving the MCP joints [31] .
Dactylitis is associated with swelling and erythema and is similar in appearance to PsA [32] . It is more common in those of African descent. Histology confirms tenosynovitis and soft tissue granulomas. Radiographs reveal cystic bone lesions, with a characteristic lattice-like appearance [33] . Joint line erosions are not characteristic, although the cystic lesions can lead to articular collapse.
Myopathy
Three distinct clinical patterns of muscle involvement in sarcoidosis are recognized: chronic myopathy, nodular myopathy and acute myopathy. Sarcoidosis patients report myalgia more commonly than healthy controls [34] . Skeletal muscle involvement has been estimated to occur in as many as half of all sarcoidosis patients [35] but is symptomatic in <3% [36] . Patients frequently report generalized weakness, fatigue and reduced exercise capacity. Assessing the extent symptoms are attributable to respiratory disease versus muscle disease is challenging [37] . Diagnostic difficulty may arise when myopathy occurs in patients on corticosteroid therapy, since corticosteroid myopathy has a similar distribution to that seen in sarcoid myopathy. Muscle biopsy is particularly helpful in distinguishing these scenarios.
Chronic sarcoid myopathy
Chronic myopathy is the most common form, mainly reported in female patients between the ages of 50 and 60 years. It manifests with insidious onset of symmetrical proximal muscle weakness; trunk and neck muscles can also be involved [38] . Patients often have normal levels of muscle enzymes, while neurophysiology demonstrates myopathic changes comparable to other inflammatory muscle disorders [36] . When performed, muscle biopsy typically shows granulomatous change alongside cellular infiltration with lymphocytes and macrophages with endomysial and perivascular inflammation [39, 40] . Muscle tissue may be abnormal in patients without muscle symptoms and represents a potential site for biopsy when other involved organs are less accessible to tissue diagnosis. MRI may reveal muscle atrophy with fatty degeneration [41] . It is notable that some of the earlier MRI studies did not include fat suppression or short tau inversion recovery sequences, which have since been shown to be more sensitive to abnormalities. In recent years FDG-PET/CT has emerged as the most sensitive imaging technique for muscle involvement [42] .
Nodular sarcoid myopathy
Nodular sarcoid myopathy is characterized by single or multiple nodules in the muscles [43] . Patients typically have symmetrical limb involvement [40, 44] . The nodules are often painful and over time can lead to contractures. Serum levels of muscle enzymes and neurophysiology studies are normal. Macroscopic histological analysis demonstrates lesions between muscle bundles without direct involvement of muscle fibres [45] . MRI is a useful modality for localizing this pattern of myopathy [46] . Nodules appear round, ovoid or fusiform, extending alongside the muscle fibres [47] . The central nodule structure demonstrates decreased signal intensity due to persistent inflammation within the central portion of the granuloma followed by fibrous tissue replacement. The peripheral area exhibits slightly increased signal intensity on T1-weighted images due to its high cellular content and displays significantly increased signal intensity on T2-weighted images due to peripheral oedema associated with the granulomatous inflammation [47] .
Acute sarcoid myopathy
Acute myopathy is the least common form of sarcoid myopathy. It tends to occur early in the course of sarcoidosis and in patients <40 years of age [40] . The clinical presentation is comparable to other inflammatory myopathies, with rapid onset of proximal weakness and myalgia associated with elevated creatinine kinase levels. Muscle biopsy shows non-caseating granulomas with pronounced lymphocytic infiltration [48] .
Bone involvement
Bone involvement is usually asymptomatic and often identified following imaging for other reasons. It is estimated to occur in 115% of patients with sarcoidosis [49] . It is seen in all ethnicities, although there is a suggestion of a racial predilection for the site of involvement, with bone cysts of the hands and feet more common in black people [50] . Bone involvement is often accompanied by overlying skin disease. Soft tissue swelling and skin involvement predates bone abnormalities and can be observed up to 4 years prior to detectable radiologic changes [51] .
Three patterns of bone lesion are described in the literature: permeative 'moth-eaten' appearance, involving the cortex of the phalanges and accompanied by soft tissue swelling; lytic lesions, also called bone cysts, which appear as cortical defects in the phalangeal heads or round punch-out lesions; and sclerotic lesions, which are seen in the spine and are similar to those seen in metastatic disease [50] . Sarcoid bone lesions are more often cystic than sclerotic or lytic.
Bone involvement is reported most frequently in the proximal and middle phalanges, but the skull, nasal bones, maxilla, sternum, ribs, vertebra, pelvis, tibia and femur may also be affected. In the literature, peripheral bone involvement is more frequently described; however, increasing use of advanced imaging modalities (PET-CT or MRI) is revealing a higher proportion of axial involvement. Sparks et al. [52] identified incidental sarcoidosis affecting the spine or pelvis in 90% of their cohort, while only 10% had isolated appendicular skeleton involvement. In this study, all patients had involvement in more than one bone site.
Serum calcium and alkaline phosphatase levels are typically normal despite multiple affected bones. This finding reflects a distinct pathophysiology compared with other diseases such as Paget's, malignancy, osteoporosis or osteomalacia [52] .
Principles of treatment
Most patients with sarcoidosis have asymptomatic nonprogressive disease or experience spontaneous remission and thus do not require treatment. Lö fgren's syndrome is a self-limiting process and in many circumstances NSAIDs are sufficient [53] .
For those with more severe disease, treatment is aimed at reducing the burden of granulomatous inflammation and preventing organ damage. For articular manifestations, prednisolone 1020 mg is usually sufficient to control acute arthritis, and in patients with chronic disease, lower doses are acceptable [20] . There are no randomized controlled trials of treatments in sarcoid myopathy, and corticosteroid regimens are similar to those used to treat inflammatory myopathies. They are generally efficacious in acute and nodular muscular sarcoidosis, although less so in chronic sarcoid myopathy. Despite initial success, a high rate of relapse is reported [44] . Intralesional injections of triamcinolone have been successfully administered for painful nodular lesions [54] .
The presence of bone involvement is often suggestive of chronic severe sarcoidosis with multiorgan involvement. Bone lesions in themselves are not an indication for specific treatment unless they are symptomatic. Corticosteroids can ameliorate soft tissue swelling but do not improve the abnormal bone architecture [55] . The therapeutic use of vitamin D should be undertaken with caution, as dysregulated calcium metabolism is well recognized in sarcoidosis secondary to extrarenal synthesis of calcitriol.
The addition of steroid-sparing agents is common in corticosteroid-refractory disease or in those who require high doses of steroids for prolonged periods. There are limited data from controlled trials to guide treatment, which must be tailored to the specific organ or organs involved. The choice of steroid-sparing agent is largely without an evidence base and thus no clear recommendation can be made.
The most evidence lies with MTX, with significant steroid-sparing potency in the treatment of sarcoid interstitial lung disease [56, 57] , thus MTX is recommended as a firstline treatment by the World Association of Sarcoidosis and Other Granulomatous Disorders [58] . There are no trials for the use of MTX in musculoskeletal sarcoidosis, and although positive case reports exist, publication bias is likely [56, 59, 60] . Our experience with MTX for musculoskeletal manifestations has been varied, with responses more apparent in people with objective synovitis and less obvious benefit in those with tenosynovitis alone. MTX has also been used in steroid-recalcitrant acute sarcoid myositis and in bone disease with varying success [60] . Fujita et al. [48] reviewed 18 patients with sarcoid myositis, reporting a successful response to corticosteroid therapy in the majority. Of the five patients with resistance to corticosteroid therapy, three were treated and responded dramatically to the addition of low-dose MTX without any marked side effects.
To facilitate steroid dose reduction in extrapulmonary sarcoidosis [61] , LEF may be utilized as an alternative or in addition to MTX; however, there is little information on its use in musculoskeletal disease. HCQ has been used successfully for acute arthritis and cutaneous involvement [62, 63] . MMF has been shown to be effective in neurosarcoidosis [64] , although MTX significantly increases the survival time without relapse and is preferred over MMF [65] . In renal disease, benefit with AZA and MMF has only reported in small case series. These agents are used instead of MTX, which is not recommended because clearance is almost exclusively via the kidneys [66] .
TNF-a plays a pivotal role in the formation of granuloma in sarcoidosis and thus is a potential therapeutic target. Several case reports have documented success in cutaneous, cardiac, neurological and musculoskeletal disease [64, 6769] . While adalimumab was found to be effective for cutaneous involvement [70] , results from larger randomized controlled trials in pulmonary disease have been disappointing [71, 72] . Currently there are no trial data to support anti-TNF use in sarcoidosis. Positive individual case reports exist with the use of rituximab in cardiac and neurological sarcoidosis [7375] .
Conclusion
Sarcoidosis remains a challenging condition to diagnose, with a myriad of manifestations within the musculoskeletal system. Demonstrating histological evidence of granulomatous inflammation is central to the diagnosis. It is vital that clinicians are aware of other granulomatous diseases that may mimic sarcoidosis. Retaining an open mind about diagnosis is essential, especially in those patients in whom the diagnosis was hardest to come by.
Treatment recommendations of musculoskeletal manifestations are largely eminence based and derived from extrapolations from the pulmonary evidence base. Globally there are no guidelines available for the management of musculoskeletal sarcoidosis. Randomized controlled trials are warranted, but given the rarity of the disease, challenging to facilitate. In addition, validated outcome measures for musculoskeletal sarcoidosis are lacking.
The role of a rheumatologist in sarcoidosis is important, ensuring both accurate syndromic diagnosis of musculoskeletal manifestations as well as bringing expertise in the management of long-term immunosuppression. 
